The Rab37/IL-6/STAT3/PD-1 axis in immune cell models prompted us to determine whether concurrent blockade of IL-6 and CTLA-4 in vivo would provide a rational treatment to circumvent current PD-1-targeted immune-modulatory therapy for lung cancer. The gene discussed is CTLA4; the disease is lung carcinoma.